NCT00305760View on ClinicalTrials.gov

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

Cetuximab

Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.

BIOLOGICAL

Pancreatic tumor vaccine

Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.

DRUG

Cyclophosphamide

Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00305760 - Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter